昌红科技(300151) - 2020 Q3 - 季度财报

Financial Performance - Operating revenue for the reporting period was ¥289,526,103.12, representing a year-on-year growth of 56.68%[8] - Net profit attributable to shareholders was ¥42,657,757.00, a significant increase of 105.40% compared to the same period last year[8] - The company reported a net profit of ¥146,088,654.26 for the year-to-date, which is an increase of 183.53% compared to the same period last year[8] - Basic earnings per share reached ¥0.0849, reflecting a growth of 105.57% compared to the previous year[8] - The company achieved an operating profit of ¥53,145,835.07, compared to ¥23,754,750.30 in the same quarter last year, reflecting a growth of 123.8%[59] - Net profit for the quarter was ¥46,616,728.96, representing a significant increase of 126.5% compared to ¥20,546,101.06 in the previous year[59] - The net profit attributable to the parent company was CNY 146,088,654.26, up from CNY 51,524,352.87, representing a significant increase[78] - The total profit for the current period was CNY 186,506,066.12, compared to CNY 58,710,827.52 in the previous period, showing a substantial growth[78] Assets and Liabilities - Total assets at the end of the reporting period reached ¥1,278,615,918.54, an increase of 20.98% compared to the end of the previous year[8] - The company's total current assets reached CNY 718,883,651.41, up from CNY 562,387,152.79, indicating a growth of about 27.8%[37] - The total liabilities of the company were CNY 237,417,693.08, up from CNY 174,243,762.69, representing a growth of approximately 36.3%[43] - Total liabilities stood at ¥155,859,186.83, up from ¥122,604,084.34, indicating a rise of 27.1%[53] - The company's equity attributable to shareholders reached CNY 1,014,549,656.20, compared to CNY 868,176,746.71, indicating an increase of about 16.8%[46] Cash Flow - The net cash flow from operating activities was ¥82,687,408.49, up 280.18% year-on-year[8] - The net cash flow from operating activities was CNY 157,645,338.47, up from CNY 106,258,441.66 year-over-year[87] - Total operating cash inflow amounted to CNY 922,702,445.95, compared to CNY 613,578,201.90 in the prior period, reflecting a significant increase[87] - Cash inflow from financing activities was CNY 20,000,000.00, compared to a cash outflow of CNY 31,274,968.86 in the previous period[90] - The net increase in cash and cash equivalents was CNY 42,164,359.82, contrasting with a decrease of CNY -59,806,150.72 in the prior year[90] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 19,409[12] - The largest shareholder, Li Huanchang and his concerted actors, held 42.24% of the shares, totaling 212,258,000 shares[12] - The company did not engage in any repurchase agreements during the reporting period[16] - The company has repurchased 5,397,500 shares, accounting for 1.07% of the total share capital, with a total transaction amount of ¥50,151,062[27] Investments and Expenses - The company's financial expenses increased significantly, showing a negative change of -161.35% due to rising bank loan interest and currency fluctuations[20] - Research and development expenses for the quarter were ¥10,331,496.08, an increase of 37.4% from ¥7,540,444.89 year-over-year[56] - Research and development expenses for the current period amounted to ¥3,543,871.99, slightly up from ¥3,294,161.76 in the previous period[64] - The company reported an investment income of ¥8,687,623.80, down from ¥29,814,170.88 in the previous period[64] - The company reported a financial expense of CNY 4,555,840.77, a decrease from CNY 7,425,731.86 in the previous period, reflecting better cost management[78] Future Outlook - The company anticipates continued growth in its medical business, contributing to a positive outlook for future performance[31] - The company plans to continue expanding its market presence and investing in new technologies to drive future growth[66]